11 results
The purpose of this study is to observe the usability of Dexmedetomidine and to determine the overall satisfaction of the patient.
Primary objective:the effects of sedation with clonidine or dexmedetomidine on the duration of haloperidol-resistent delirium in intensive care patientsSecondary objectives:the effect of treatment with clonidine or dexmedetomidine on1. total of…
The purpose of this study is to observe the usability of dexmedetomidine compared to the standard therapy (propofol) and to determine the overall satisfaction of the patient.
The aim of this study is to determine the patients* and endoscopists experiences and patients* safety with different sedation protocols.
Primary objective:The study has hierarchical co-primary objectives to demonstrate that:- Firstly: dexmedetomidine is at least as effective as sedation with propofol and daily sedation stops, in maintaining a target depth of sedation in ventilated…
This study aims to evaluate the safety, tolerability and sedative proporties of a single dose of intransally administered dexmedetomidine in person odler than 65 years, differentiating between person using beta-blocking medication and those not…
To demonstrate non-inferiority of conscious sedation with intranasal dexmedetomidine for performing dental care in patients with intellectual disability and dentophobia.
The primary objective is to assess long-term safety of study drug(s) in subjects who are enrolled in Eisai-sponsored lenvatinib studies.
Primary ObjectiveTo evaluate whether lenvatinib in combination with ifosfamide and etoposide (Arm A) is superior to ifosfamide and etoposide (Arm B) in improving progression-free survival (PFS) by independent imaging review [IIR] using Response…
To compare pembrolizumab plus lenvatinib in combination with TACE versus placebo plus TACE with regard to progression-free survival (PFS) per RECIST 1.1 assessed by blinded, independent central review (BICR)
Primary ObjectiveTo assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile…